Lumos Diagnostics Holdings Ltd. LDX
ASX · Australia · Health Technology
AUD 0.10000.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has expanded the live rollout of its FebriDx rapid diagnostic test to 215 US urgent care sites, up from 170, as commercial traction builds across major health-system-owned networks. The number of sites actively evaluating FebriDx has also...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has entered the new financial year with a significantly expanded US opportunity for its FebriDx rapid diagnostic test after securing regulatory, reimbursement and distribution milestones during the 12 months to June 30, 2026. Revenue for the...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) is moving into the commercial phase of its US FebriDx strategy after securing the regulatory clearance, distribution network and funding needed to pursue the outpatient healthcare market. oppurtunity The US Food and Drug Administration...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a US$767,800 purchase order for its FebriDx® rapid diagnostic test from US distribution partner PHASE Scientific, marking further progress in the product’s commercial rollout. The order will be fulfilled progressively through...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has expanded the European commercial footprint of its FebriDx rapid diagnostic test after signing an exclusive distribution agreement with Romanian healthcare supplier Alpha Medical. Under the agreement, Alpha Medical will manage sales,...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) finished the fourth quarter of FY26 with strong full-year growth from its flagship FebriDx® rapid diagnostic test, expanding US commercial adoption and closing the period with US$15.4 million in cash. Unaudited FY26 revenue increased 6% on...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured the rollout of its FebriDx rapid diagnostic test across more than 30 US urgent care sites and advanced three additional major healthcare groups, representing more than 230 sites, into clinical and economic validation. Together,...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a A$709,837 cash refund under the Australian Government’s Research and Development Tax Incentive, strengthening its capacity to advance its rapid point-of-care diagnostic technology platforms. The refund relates to eligible...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has reported encouraging early progress in the US commercial rollout of its FebriDx® rapid respiratory infection test following recent FDA CLIA waiver clearance, with reimbursement performance and customer adoption tracking positively ahead of...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has completed a further milestone under its BARDA-funded FebriDx® paediatric clinical study, enrolling 250 patients in the trial. The achievement marks milestone number 7 under the company’s agreement with the Biomedical Advanced Research...
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has received a further milestone payment of just over US$500,000 from the US Biomedical Advanced Research and Development Authority (BARDA) after securing CLIA waiver status for its FebriDx® rapid respiratory infection test, adding fresh...
Trump warned the US would step up strikes on Iran over the next two to three weeks
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.